Cardiovascular Risk Factors With HIV Infection: A Long and Motley List
References and Notes
- Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
- Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-e35. Erratum in Circulation. 2008;118:e108.
- Centers for Disease Control and Prevention. Heart disease. Heart disease facts.
- Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-270.
- Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537-1548. Erratum in AIDS. 2011;25:883.
- Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006;43:27-34.
- Henard S, Roussillon C, Bonnet F, et al. Cardiovascular-related deaths in HIV+ patients between 2000 and 2010: Agence Nationale de Recherche sur le Sida EN20 Mortalité 2010 Survey. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 1048.
- Centers for Disease Control and Prevention. Heart disease. Heart disease risk factors.
- Althoff K, Wyatt C, Gibert C, et al. HIV+ adults are at greater risk for myocardial infarction, non-AIDS cancer, and end-stage renal disease, but events occur at similar ages compared to HIV- adults. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 59.
- Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
- Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126-136.
- Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-1230.
- Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512.
- Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-1631.
- Stein JH. Carotid artery imaging: insights into inflammation and cardiovascular disease risk in patients with HIV infection. J Am Heart Assoc. 2012;1:e001396.
- Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
- Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. February 12, 2013.
- Freiberg MS, Chang CCH, Kuller LH, et al. HIV infection and risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-622.
- Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351-358.
- Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart. 2009;95:1826-1835.
- Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608.
- Ross AC, Storer N, O'Riordan MA, Dogra V, McComsey GA. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J. 2010;29:634-638.
- Patel K, Dyke RB, Mittleman MA, et al. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. AIDS. 2012;26:2027-2037.
- Department of Health and Human Services. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. July 31, 2012.
- Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil. 2010;17:491-501.
- Centers for Disease Control and Infection. Cholesterol. America's cholesterol burden.
- Buchacz K, Baker RK, Palella FJ Jr, et al; HIV Outpatient Study investigators. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013; 18:65-75.
- Dubé MP, Stein JH, Aberg JA, et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
- Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497-1504.
- European AIDS Clinical Society. EACS Guidelines. Version 6.1. November 2012.
- Stein JH. Cardiovascular risk and dyslipidemia management in HIV-infected patients. Top Antivir Med. 2012;20:129-133.
- Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
- Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735-742.
- Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-2564.
- Lichtenstein K, Debes R, Wood K, et al. Statin use is associated with incident diabetes mellitus among patients in the HIV Outpatient Study. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 767.
- Drechsler H, Zhang S, Maalouf N, et al. Impact of statin exposure on mortality and non-AIDS complications in HIV patients on HAART. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 765.
- Lichtenstein KA, Armon C, Buchacz K, et al; HOPS investigators. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis. 2013;10:E10.
- Centers for Disease Control and Prevention. High blood pressure. High blood pressure facts.
- Cerrato E, D'Ascenzo F, Biondi-Zoccai G, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013; Jan 18. Epub ahead of print.
- Nüesch R, Wang Q, Elzi L, al; the Swiss HIV Cohort Study. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr. 2013; Jan 2. Epub ahead of print.
- Centers for Disease Control and Prevention. Diabetes Public Health Resource. 2011 National Diabetes Fact Sheet.
- Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients -- association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
- Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404-410.
- Smith CJ, Levy I, Sabin CA, et al. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med. 2004;5:88-92.
- Monroe AK, Dobs AS, Xu X, et al. Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. J Acquir Immune Defic Syndr. 2011;58:173-180.
- Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23: 1227-1234.
- Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61:334-340.
- Diabetes UK. State of the Nation 2012 England.
- Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-1184.
- Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739-1745.
- Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303-314.
- Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111-119.
- Centers for Disease Control and Prevention. Overweight and obesity. Causes and consequences.
- Centers for Disease Control and Prevention. Overweight and obesity. Adult obesity facts.
- Thompson-Paul A, Wei S, Mattson C, Skarbinski J. Prevalence of obesity in a nationally representative sample of HIV+ adults receiving medical care in the US: Medical Monitoring Project, 2009. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 777.
- Lake JE, Wohl D, Scherzer R, et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care. 2011;23:929-938.
- Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012;61:600-605.
- Tate T, Willig A, Willig J, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17:1281-1989.
- Janiszewski PM, Ross R, Despres JP, et al. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study. PLoS One. 2011;6:e25032.
- Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. From wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Human Retroviruses. 2013;29:435-440.
- Hendricks KM, Willis K, Houser R, Jones CY. Obesity in HIV-infection: dietary correlates. J Am Coll Nutr. 2006;25:321-331.
- Joy T, Keogh HM, Hadigan C, et al. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS. 2007;21:1591-1600.
- Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290.
- Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009;169:659-669.
- Ng GW, Chan UM, Li PC, Wong WC. Can a Mediterranean diet reduce the effects of lipodystrophy syndrome in people living with HIV? A pilot randomised controlled trial. Sex Health. 2011;8:43-51.
- Tsiodras S, Poulia KA, Yannakoulia M, et al. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism. 2009;58:854-859.
- Panagiotakos DB, Pitsavos C, Arvaniti F, Stefanadis C. Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore. Prev Med. 2007;44:335-340.
- Turcinov D, Stanley C, Canchola JA, Rutherford GW, Novotny TE, Begovac J. Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy. Coll Antropol. 2009;33:423-430.
- Turcinov D, Stanley C, Rutherford GW, Novotny TE, Begovac J. Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy. Eur J Epidemiol. 2009;24:267-274.
- Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS. 2006;20:1843-1850.
- Stein JH, Hadigan CM, Brown TT, et al. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation. 2008;118:e54-e60.
- Mdodo R, Frazier E, Mattson C, Sutton M, Brooks J, Skarbinski J. Cigarette smoking among HIV+ adults in care: Medical Monitoring Project, US, 2009. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 775.
- Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR; INSIGHT SMART Study Group. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896-1903.
- SMART investigators calculated the population-attributable risk percent of a clinical endpoint attributable to smoking as Pe (HR - 1) / [Pe (HR - 1) + 1], where Pe was the proportion of the population with the exposure (for example, the proportion who reported current smoking at baseline) and HR represented the relative risk estimate.
- Petoumenos K, Worm S, Reiss P, et al; D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011;12:412-421.
- Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727-734.
- Fitch KV, Looby SE, Rope A, Eneh P, Hemphill L, Lee H, Grinspoon SK. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS. 2013;27:49-57.
- Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS. 2002;16:39-42.
- Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans. J Gen Intern Med. 2007;22:749-754.
- US Department of Health and Human Services. Clinical Practice Guideline. Treating tobacco use and dependence. 2008 update.
- National Heart Lung and Blood Institute. Strategies to quit smoking.
- Centers for Disease Control and Prevention. Alcohol and public health. Fact sheets -- alcohol use and health.
- Rehm J, Gmel G, Sepos CT, Trevisan M. Alcohol-related morbidity and mortality. Alcohol Res Health. 2003;27:39-51.
- Freiberg MS, McGinnis KA, Kraemer K, et al; VACS Project Team. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr. 2010; 53:247-253.
- Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22:1355-1363.
- Colfax G, Coates TJ, Husnik MJ, et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health. 2005; 82(1 suppl 1):i62-i70.
- Youth Risk Behavior Survey. Trends in the prevalence of marijuana, cocaine, and other illegal drug use national YRBS: 1991-2011.
- Carrillo X, Curós A, Muga R, Serra J, Sanvisens A, Bayes-Genis A. Acute coronary syndrome and cocaine use: 8-year prevalence and in-hospital outcomes. Eur Heart J. 2011;32:1244-1250.
- Lai S, Lima JA, Lai H, et al. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med. 2005;165:690-695.
- Lai S, Fishman EK, Lai H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis. 2008;46:600-610.
- National Kidney Foundation. Kidney disease. How your kidneys work.
- National Kidney Foundation. Kidney disease. About chronic kidney disease.
- Garg S, Furlow-Parmley C, Frazier D, Skarbinski J. Prevalence of chronic kidney disease among HIV+ adults in care in the US: Medical Monitoring Project, 2009. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta. Abstract 809.
- Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651-658.
- National Kidney Foundation. Kidney disease. Albuminuria.
- George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24:387-394.
- Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
- Szczech LA, Grunfeld C, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS. 2007;21:1003-1009.
- Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging. 2012;32:421-430.
- Tien PC, Schneider MF, Cole SR, et al. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's Interagency HIV Study. AIDS. 200;23:1781-1784.
- Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Weber R, Sabin C, Reiss P, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther. 2010;15:1077-1086.
- Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-468.
- Kakinami L, Block RC, Adams MJ, Cohn SE, Maliakkal B, Fisher SG. Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int J Clin Pract. 2013;67:6-13.
- Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis. 2012;222:274-277.
- Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
- Lang J, Scherzer R, Weekley CC, Tien PC, Grunfeld C, Shlipak MG. Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans. AIDS. 2013 Jan 22. Epub ahead of print.
- Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis. 2011;214:468-473.
- Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003;32:210-214.
- Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-273.
- Choi AI, Lo JC, Mulligan K, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis. 2011;52:941-944.
- Ross AC, Judd S, Kumari M, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther. 2011;16:555-563.
- Shikuma CM, Seto T, Liang CY, et al. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses. 2012;28:793-797.
- Eckard AR, Tangpricha V, Seydafkan S, et al. The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults. Pediatr Infect Dis J. 2013 Jan 28. Epub ahead of print.
- Pludowski P, Holick MF, Pilz S, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality -- a review of recent evidence. Autoimmun Rev. 2013 Mar 28. Epub ahead of print.
- Longenecker CT, Hileman CO, Carman TL, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613-621.
- Womack JA, Scherzer R, Cole SR, et al. Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection. J Acquir Immune Defic Syndr. 2009;52:581-587.
No comments have been made.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy